PATENT CLAIM ANALYSIS

Application Number: 16020814
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-07
Patent Classification: ["544", "311000"]

Abstract:
The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.

Claim (Index 13):
A pharmaceutical composition comprising amorphous 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid sodium salt (compound 5-1) having an impurity profile of  claim 12 , and a pharmaceutically acceptable carrier and/or diluent.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 94.0
- Lexical Diversity: 1.14815
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12741819', '15833513', '14309732', '15406476', '13511065']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7302930925350988
- 35 USC 102 Novelty (BERT): 0.4974792272494835
- Combined Prediction Score: 0.7070117060065373
- Mean Citation Score: 210.544106
- Max Citation Score: 218.25853
- Similarity Product: 142.69252476850212

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test